{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T02:18:28Z","timestamp":1795141108306,"version":"4.10.3"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","funder":[{"name":"Allergan Foundation"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To compare combined dexamethasone implant and intravitreal aflibercept (AFB) to AFB monotherapy treatment in diabetic macular edema (DME).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This open-label randomized clinical trial involved randomization of patients with DME (n = 50) to pro re nata treatment with combined dexamethasone and AFB or AFB alone according to prespecified retreatment criteria. Best-corrected visual acuity, central subfield retinal thickness (CST), and adverse events were monitored monthly for 48 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The combined treatment and the AFB monotherapy group demonstrated CST reductions at each visit. The difference (95% confidence intervals [CI]) in the change from baseline in CST between the groups was \u221232.9 (\u221281.5 to 15.6)\n                      <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>\n                      m at week 48, favoring the combination therapy group without significance (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.183). The difference in the change from baseline in best-corrected visual acuity was \u22123.3 (\u22129.2 to 2.5) letters read at week 48 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.266). Injection number was numerically higher in the aflibercept monotherapy group (mean \u00b1 SD, 5.9 \u00b1 1.8) than in the combination group (4.9 \u00b1 1.5). The AFB monotherapy group had a 90% higher injection rate over the study period (incidence rate ratio [95% CI] = 1.9 [0.9\u20134.0]) without statistical significance (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.081). The combined treatment group achieved quicker time to resolution of DME (log-rank\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      -value = 0.013) by a median difference (95% CI) of 12 (0\u201324) weeks. Three eyes and two eyes in the combined therapy group developed worsening cataracts and intraocular pressure elevation requiring medical management, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Combined treatment achieved similar anatomic and visual outcomes compared with AFB monotherapy, with quicker DME resolution but higher cataract and intraocular pressure risks.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004858","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T14:02:03Z","timestamp":1775743323000},"page":"1520-1531","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["DEXAMETHASONE IMPLANT AND AFLIBERCEPT COMBINATION THERAPY VERSUS AFLIBERCEPT MONOTHERAPY FOR DIABETIC MACULAR EDEMA"],"prefix":"10.1097","volume":"46","author":[{"given":"Irene Park","family":"Kim","sequence":"first","affiliation":[{"name":"Wills Eye Hospital Retina Service, Mid Atlantic Retina, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Orndahl","sequence":"additional","affiliation":[{"name":"The Emmes Company, LLC, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Nyaiburi","sequence":"additional","affiliation":[{"name":"The Emmes Company, LLC, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Anand","sequence":"additional","affiliation":[{"name":"Texas Retina Associates, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Callanan","sequence":"additional","affiliation":[{"name":"Texas Retina Associates, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Chong","sequence":"additional","affiliation":[{"name":"Texas Retina Associates, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Coors","sequence":"additional","affiliation":[{"name":"Texas Retina Associates, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Fuller","sequence":"additional","affiliation":[{"name":"Texas Retina Associates, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"McClellan","sequence":"additional","affiliation":[{"name":"Texas Retina Associates, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Solley","sequence":"additional","affiliation":[{"name":"Texas Retina Associates, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wang","sequence":"additional","affiliation":[{"name":"Texas Retina Associates, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Williams","sequence":"additional","affiliation":[{"name":"Texas Retina Associates, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Yonekawa","sequence":"additional","affiliation":[{"name":"Wills Eye Hospital Retina Service, Mid Atlantic Retina, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8719-6709","authenticated-orcid":false,"given":"Ashkan Michael","family":"Abbey","sequence":"additional","affiliation":[{"name":"Texas Retina Associates, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20261120","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/S0161-6420(03)00568-2","article-title":"Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema","volume":"110","author":"Funatsu","year":"2003","journal-title":"Ophthalmology"},{"key":"R3-20261120","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/2474126419834711","article-title":"Evidence-based guidelines for management of diabetic macular edema","volume":"3","author":"Bakri","year":"2019","journal-title":"J Vitreoretin Dis"},{"key":"R4-20261120","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial","volume":"123","author":"Wells","year":"2016","journal-title":"Ophthalmology"},{"key":"R5-20261120","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","author":"Wells","year":"2015","journal-title":"N Engl J Med"},{"key":"R6-20261120","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1001\/jamaophthalmol.2017.6565","article-title":"Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial","volume":"136","author":"Bressler","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"R7-20261120","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1248\/bpb.31.1541","article-title":"Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion Molecule-1 expression","volume":"31","author":"Wang","year":"2008","journal-title":"Biol Pharm Bull"},{"key":"R8-20261120","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3390\/pharmaceutics12080703","article-title":"Intravitreal dexamethasone implant as a sustained release drug delivery device for the treatment of ocular diseases: a comprehensive review of the literature","volume":"12","author":"Iovino","year":"2020","journal-title":"Pharmaceutics"},{"key":"R9-20261120","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.2147\/OPTH.S79948","article-title":"Dexamethasone intravitreal implant in the treatment of diabetic macular edema","volume":"9","author":"Dugel","year":"2015","journal-title":"Clin Ophthalmol (Auckland, N.Z.)"},{"key":"R10-20261120","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0002-9394(02)01323-5","article-title":"Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders","volume":"133","author":"Funatsu","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"R12-20261120","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","article-title":"Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema","volume":"121","author":"Boyer","year":"2014","journal-title":"Ophthalmology"},{"key":"R13-20261120","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/bjophthalmol-2021-319070","article-title":"Dexamethasone intravitreal implant in treatment-na\u00efve diabetic macular oedema: findings from the prospective, multicentre, AUSSIEDEX study","volume":"107","author":"Fraser-Bell","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"R14-20261120","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/j.ophtha.2014.07.002","article-title":"A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study","volume":"121","author":"Gillies","year":"2014","journal-title":"Ophthalmology"},{"key":"R15-20261120","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1097\/IAE.0000000000002537","article-title":"Comparison of intravitreal dexamethasone implant and aflibercept in patients with treatment-naive diabetic macular edema with serous retinal detachment","volume":"40","author":"Ozsaygili","year":"2020","journal-title":"Retina"},{"key":"R16-20261120","doi-asserted-by":"crossref","first-page":"S453","DOI":"10.4103\/IJO.IJO_2310_23","article-title":"Comparison of ranibizumab, aflibercept, and dexamethasone implant monotherapy in treatment-naive eyes with diabetic macular edema: a 12-month real-life experience","volume":"72","author":"Parca","year":"2024","journal-title":"Indian J Ophthalmol"},{"key":"R17-20261120","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamaophthalmol.2017.4914","article-title":"Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR network phase 2 randomized clinical trial","volume":"136","author":"Maturi","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"R18-20261120","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00592-021-01824-5","article-title":"Therapeutic effect of simultaneous intravitreal dexamethasone and aflibercept on diabetic macular edema","volume":"59","author":"Lin","year":"2022","journal-title":"Acta Diabetol"},{"key":"R19-20261120","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s10792-024-02963-8","article-title":"Does dexamethasone implant combination with aflibercept monotherapy affect one-year outcomes in treatment-naive diabetic macular edema with inflammatory biomarkers?","volume":"44","author":"Ozsayg\u0131l\u0131","year":"2024","journal-title":"Int Ophthalmol"},{"key":"R20-20261120","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s10792-017-0496-4","article-title":"Intravitreal bevacizumab alone or combined with 1 mg triamcinolone in diabetic macular edema: a randomized clinical trial","volume":"38","author":"Riazi-Esfahani","year":"2018","journal-title":"Int Ophthalmol"},{"key":"R21-20261120","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000489345","article-title":"Sequential dexamethasone and aflibercept treatment in patients with diabetic macular edema: structural and functional outcomes at 52 weeks","volume":"241","author":"Hern\u00e1ndez-Bel","year":"2019","journal-title":"Ophthalmologica"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/IAE.0000000000004858","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T02:00:26Z","timestamp":1795140026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/IAE.0000000000004858"}},"subtitle":["A Prospective, Comparative Trial (COED Trial)"],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004858","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}